US Bancorp
- SEC CIK
- 0000036104
- Latest filing
- Aug 12, 2026
AKRO holding history
Akero Therapeutics, Inc. in every 13F filed by US Bancorp, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
AKRO overviewAll 13F holders of AKROFull Q2 2026 holdings
- Shares (Q4 2025)
- 0
- Sold out in Q4 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 19
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2025 | 0 | $0 | 0.0% | −3,664−100.0% | Sold out | Holders |
| Q3 2025 | 3,664 | $174.0K | <0.1% | +599+19.5% | Added | Holders |
| Q2 2025 | 3,065 | $163.5K | <0.1% | +1,300+73.7% | Added | Holders |
| Q1 2025 | 1,765 | $71.4K | <0.1% | +46+2.7% | Added | Holders |
| Q4 2024 | 1,719 | $47.8K | <0.1% | +8+0.5% | Added | Holders |
| Q3 2024 | 1,711 | $49.1K | <0.1% | −50−2.8% | Reduced | Holders |
| Q2 2024 | 1,761 | $41.3K | <0.1% | +48+2.8% | Added | Holders |
| Q1 2024 | 1,713 | $43.3K | <0.1% | −1,464−46.1% | Reduced | Holders |
| Q4 2023 | 3,177 | $74.2K | <0.1% | +907+40.0% | Added | Holders |
| Q3 2023 | 2,270 | $114.8K | <0.1% | −1,391−38.0% | Reduced | Holders |
| Q2 2023 | 3,661 | $170.9K | <0.1% | +436+13.5% | Added | Holders |
| Q1 2023 | 3,225 | $123.4K | <0.1% | −4,208−56.6% | Reduced | Holders |
| Q4 2022 | 7,433 | $407.3K | <0.1% | +1,892+34.1% | Added | Holders |
| Q3 2022 | 5,541 | $189.0K | <0.1% | +3,286+145.7% | Added | Holders |
| Q2 2022 | 2,255 | $21.0K | <0.1% | +879+63.9% | Added | Holders |
| Q1 2022 | 1,376 | $20.0K | <0.1% | +276+25.1% | Added | Holders |
| Q4 2021 | 1,100 | $23.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2021 | 1,100 | $25.0K | <0.1% | −1,931−63.7% | Reduced | Holders |
| Q2 2021 | 3,031 | $75.0K | <0.1% | −969−24.2% | Reduced | Holders |
| Q1 2021 | 4,000 | $116.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.